| Gene Symbol | ent-gene-28e2cb01 |
| Phagocytosis | TREM2 activation enhances microglial clearance of amyloid-beta plaques and cellular debris |
| Metabolic reprogramming | TREM2 signaling supports the inflammatory metabolic state of disease-associated microglia (DAM) |
| Survival signaling | TREM2 provides pro-survival signals that prevent microglial apoptosis |
| Clustering | TREM2 promotes microglial clustering around amyloid plaques, forming a protective barrier |
| Phase 1 (completed) | Demonstrated dose-dependent engagement of TREM2 and acceptable safety profile in healthy volunteers and AD patients |
| Phase 2 (INVOKE-2, ongoing) | Evaluating clinical efficacy in patients with mild-to-moderate Alzheimer's disease |
| Primary endpoints | Change in amyloid PET, cognitive measures (ADAS-Cog13, ADCS-ADL) |
| Status | Phase 1 completed, clinical development continued with strategic partner |
| Baseline sTREM2 | May predict response to TREM2 agonists |
| Dynamic changes | Treatment-induced sTREM2 increase indicates target engagement |
| R47H carriers | ~3-4x increased AD risk; reduced ligand binding |
| R62H carriers | Intermediate risk; partial loss of function |
| KG Connections | 94 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!